For the current week, the overall ratings of three Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

VIVUS Inc. (NASDAQ:VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of April 26, 2013, 26.2% of outstanding VIVUS Inc. shares were held short. To get an in-depth look at VVUS, get Portfolio Grader’s complete analysis of VVUS stock.

The rating of Cempra Holdings LLC (NASDAQ:CEMP) declines this week from a C to a D. Cempra, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage pharmaceutical company, which focuses on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin st… The stock gets F’s in Equity and Cash Flow. The stock price has dropped 8.3% over the past month, worse than the 1% increase the Nasdaq has seen over the same period of time.

For a full analysis of CEMP stock, visit Portfolio Grader.

Corcept Therapeutics’ (NASDAQ:CORT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CORT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.